Author:
Mathias Priyanka M.,Epstein Eric J.
Reference17 articles.
1. Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies;Elliot;Clin Med,2016
2. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences;Tseng;Ann Pharmacother,2017
3. Gilead SciencesGENVOYA® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) Highlights of prescribing information. Available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf. Accessed June 1, 2020.
4. A review of the efficacy and safety of Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in the management of HIV-1 infection;Angione;J Pharm Pract,2018
5. A method for estimating the probability of adverse drug reactions;Naranjo;Clin Pharmacol Ther,1981
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献